Prolactin and luteinizing hormone‐releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer

Tibor Kadar, Menashe Ben‐David, J. Edson Pontes, Matyas Fekete, Andrew V. Schally

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Using a sensitive micromethod for the determination of prolactin (PRL) binding sites based on 125I-human PRL ligand, PRL receptor levels in specimens of benign prostatic hyperplasia (BPH) and human prostate cancer were estimated by the one-point assay system. Ten of 19 BPH specimens (53%), showed significant PRL binding, for being in the 9-12 fmol/mg range. All ten of these cases had an histological diagnosis of nodular glandular hyperplasia. Of ten adenocarcinomas examined, four samples (40%) exhibited positive PRL binding, the highest receptor levels being 10.2 fmol/mg protein. To characterize the receptors from BPH membranes, samples were then separately pooled according to the results obtained in one-point assays. In the PRL-negative pool no displacement could be detected. In the PRL-positive pool, the Scatchard analysis revealed one class of receptors with an average affinity K(d) = 1.1 x 10-9 M and capacity B(max) = 287 fmol/mg protein. In the prostate cancer specimens, luteinizing hormone-releasing hormone receptors with a high affinity and a low capacity were also found. The results indicate the presence of prolactin receptors in prostate cancer and in BPH. The clinical implications of such findings are not clear, but it is possible that a certain proportion of BPH and prostate cancers might be in part PRL dependent. Further studies are necessary to ascertain this hypothesis in an attempt to improve the treatment of BPH and prostate cancer.

Original languageEnglish (US)
Pages (from-to)299-307
Number of pages9
JournalThe Prostate
Issue number4
StatePublished - 1988
Externally publishedYes


  • BPH
  • LH‐RH receptors
  • prolactin binding

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Prolactin and luteinizing hormone‐releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer'. Together they form a unique fingerprint.

Cite this